Literature DB >> 9458097

Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas.

J Y Lee1, S M Dong, W S Park, N J Yoo, C S Kim, J J Jang, J G Chi, B Zbar, I A Lubensky, W M Linehan, A O Vortmeyer, Z Zhuang.   

Abstract

Cerebellar hemangioblastoma is a benign central nervous system neoplasm with characteristic proliferation of vascular and stromal cells. There is increasing evidence that the stromal cell population may represent the neoplastic component of hemangioblastoma, whereas the vascular component may be composed of reactive, nonneoplastic cells. Therefore, successful genetic testing for loss of heterozygosity requires selective analysis of target cell populations. Here, tissue microdissection was used to selectively analyze the stromal cell component of 20 archival sporadic cerebellar hemangioblastomas for loss of heterozygosity at the Von-Hippel Lindau (VHL) gene and somatic VHL gene mutations. Allelic deletions at the VHL gene locus were detected in the stromal cell component with one or more markers (D3S1038, D3S1110, and/or 104/105) in 10 of 19 (52.6%) informative cases. In all cases, heterozygosity at the VHL gene locus was retained in the vascular component. In two cases, aberrant bands in exon 2 of the VHL gene were demonstrated in the stromal cells by PCR-based single-strand conformation polymorphism analysis, and somatic missense mutations were successfully characterized in two of the sporadic hemangioblastomas by direct sequencing. The results suggest that allelic losses and mutations of the VHL tumor suppressor gene play a role in sporadic cerebellar hemangioblastoma tumorigenesis. Furthermore, because the genetic changes were detected in selectively procured stromal cell areas, the data provide strong evidence that the stromal cell represents a neoplastic component of hemangioblastoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9458097

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Third-line sunitinib treatment in a VHL-mutated metastatic intrahepatic cholangiocarcinoma: a case report and literature review.

Authors:  Xiaofen Li; Limin Gao; Li Zhang; Hongna Sun; Hongfeng Gou
Journal:  Cancer Biol Ther       Date:  2020-06-18       Impact factor: 4.742

2.  VHL-deficient vasculogenesis in hemangioblastoma.

Authors:  Sven Gläsker; Jonathan Smith; Mark Raffeld; Jie Li; Edward H Oldfield; Alexander O Vortmeyer
Journal:  Exp Mol Pathol       Date:  2014-01-04       Impact factor: 3.362

3.  Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.

Authors:  David Taïeb; Anne Barlier; Chunzhang Yang; Morgane Pertuit; Aurélie Tchoghandjian; Claire Rochette; Hélène Zattara-Canoni; Dominique Figarella-Branger; Zhengping Zhuang; Karel Pacak; Philippe Metellus
Journal:  J Neurooncol       Date:  2015-10-29       Impact factor: 4.130

4.  Reconsideration of biallelic inactivation of the VHL tumour suppressor gene in hemangioblastomas of the central nervous system.

Authors:  S Gläsker; B U Bender; T W Apel; V van Velthoven; L M Mulligan; J Zentner; H P Neumann
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

5.  Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis.

Authors:  Jörn Karhausen; Glenn T Furuta; John E Tomaszewski; Randall S Johnson; Sean P Colgan; Volker H Haase
Journal:  J Clin Invest       Date:  2004-10       Impact factor: 14.808

6.  Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.

Authors:  Stefanie Galbán; Jennifer L Martindale; Krystyna Mazan-Mamczarz; Isabel López de Silanes; Jinshui Fan; Wengong Wang; Jochen Decker; Myriam Gorospe
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

7.  Mutations in the von hippel-lindau tumour suppressor gene in central nervous system hemangioblastomas.

Authors:  Cezary Cybulski; Joanna Matyjasik; Marianna Soroka; Janusz Szymaś; Bohdan Górski; Tadeusz Debniak; Anna Jakubowska; Andrzej Bernaczyk; Lech Zimnoch; Grazyna Bierzyńska-Macyszyn; Tomasz Trojanowski; Teresa Wierzba-Bobrowicz; Edmund Prudlak; Alicja Markowska-Wojciechowska; Przemysław Nowacki; Andrzej Roszkiewicz; Radzisław Kordek; Tadeusz Szylberg; Ewa Matyja; Krzysztof Zieliński; Bogdan Woźniewicz; Anna Taraszewska; Wojciech Kozłowski; Jan Lubiński
Journal:  Hered Cancer Clin Pract       Date:  2004-03-15       Impact factor: 2.857

8.  A vitronectin M381T polymorphism increases risk of hemangioblastoma in patients with VHL gene defect.

Authors:  Jing-Shan Huang; Chih-Ming Lin; Yu-Che Cheng; Kun-Long Hung; Chih-Cheng Chien; Shao-Kuan Chen; Chih-Ju Chang; Chan-Wei Chen; Chi-Jung Huang
Journal:  J Mol Med (Berl)       Date:  2009-03-14       Impact factor: 4.599

9.  Disseminated hemangioblastomatosis of the central nervous system without von Hippel-Lindau disease: a case report.

Authors:  Hong-Rae Kim; Yeon-Lim Suh; Jong-Won Kim; Jung-Il Lee
Journal:  J Korean Med Sci       Date:  2009-07-30       Impact factor: 2.153

10.  Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes.

Authors:  Valentina Bangiyeva; Ava Rosenbloom; Ashlynn E Alexander; Bella Isanova; Timothy Popko; Alan R Schoenfeld
Journal:  BMC Cancer       Date:  2009-07-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.